3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Genitourinary
1
Conditions
Motor Activity
236
Breast Neoplasms
128
Neoplasms
103
Prostatic Neoplasms
35
Fatigue
34
Obesity
24
Lung Neoplasms
23
Colorectal Neoplasms
22
Polycystic Ovary Syndrome
17
Colonic Neoplasms
16
Ovarian Neoplasms
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Pancreatic Neoplasms
11
Lymphoma
11
Carcinoma, Non-Small-Cell Lung
11
Weight Loss
10
Rectal Neoplasms
10
Multiple Myeloma
10
Lymphedema
10
Hematologic Neoplasms
10
Head and Neck Neoplasms
10
Leukemia
9
Insulin Resistance
8
Cardiotoxicity
8
Stomach Neoplasms
7
Peripheral Nervous System Diseases
6
Cognitive Dysfunction
6
Cachexia
6
Brain Neoplasms
6
Overweight
5
Interventions
pembrolizumab
3
atezolizumab
2
Sugammadex
2
Saline Solution
2
Paclitaxel
2
Neostigmine
2
Gemcitabine
2
Cetuximab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
lenvatinib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
delta 24-sterol reductase
1
daratumumab
1
cabozantinib
1
abemaciclib
1
Zoledronic Acid
1
Water
1
Valproic Acid
1
Urinary Diversion
1
Ultrasonography
1
Trastuzumab
1
Tomography, Optical Coherence
1
Tissue Banks
1
Therapeutics
1
Testosterone Propionate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
Exercise
×
Clear all
NCT04088968
2024-03-22
STRONG-CS
Bispebjerg Hospital
Phase NA
Unknown
100 enrolled